New results from the OMICS study, the company's prospective, international, multi-center study, show Universal DX's blood test can detect colorectal advanced adenomas at 55% sensitivity and 90% specificity, which exceeds currently available non-invasive tests for colorectal cancer screening
80% of sporadic colorectal cancers arise from pre-malignant advanced adenomas, making early detection critical to saving lives
New results from the OMICS study, which will be presented at ASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity/97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening. Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ranging between $30B and $75B in the U.S. alone
Read MoreAccording to the new market research report launched by Inkwood Research, The Global Liquid Biopsy market was valued at nearly 740 million in 2017 and is anticipated to reach around $4740 million by 2026, growing at an estimated CAGR of 22.97%, during the forecast period 2018-2026.
Read More